{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:33:34Z","timestamp":1789007614887,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006453","name":"Taisho Toyama Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ard.2026.02.004","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:35:20Z","timestamp":1772253320000},"page":"609-619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity: a randomised, controlled trial (SORAIRO trial)"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0729-9810","authenticated-orcid":false,"given":"Yuki","family":"Imai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihito","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihisa","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumiko","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-5765","authenticated-orcid":false,"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2026.02.004_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ard.2026.02.004_bib0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.004_bib0003","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.02.004_bib0004","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/ard.2009.121491","article-title":"Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study","volume":"69","author":"Tanaka","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.004_bib0005","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/S2665-9913(23)00070-X","article-title":"Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial","volume":"5","author":"Tamai","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2026.02.004_bib0006","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3899\/jrheum.151009","article-title":"Methotrexate dosage reduction upon adalimumab initiation: clinical and ultrasonographic outcomes from the randomized noninferiority MUSICA trial","volume":"43","author":"Kaeley","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2026.02.004_bib0007","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","article-title":"Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial","volume":"381","author":"Smolen","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2026.02.004_bib0008","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/art.41589","article-title":"Etanercept or methotrexate withdrawal in rheumatoid arthritis patients in sustained remission","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.02.004_bib0009","doi-asserted-by":"crossref","first-page":"R135","DOI":"10.1186\/ar4315","article-title":"Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study","volume":"15","author":"Hirata","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2026.02.004_bib0010","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1136\/annrheumdis-2018-213416","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.004_bib0011","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/rheumatology\/kex358","article-title":"Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial","volume":"57","author":"Edwards","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2026.02.004_bib0012","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","article-title":"Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.004_bib0013","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/mr\/road038","article-title":"Structural, nonclinical, and clinical features of ozoralizumab: a novel tumour necrosis factor inhibitor","volume":"33","author":"Takeuchi","year":"2023","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ard.2026.02.004_bib0014","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/art.42273","article-title":"Phase II\/III results of a trial of anti\u2013tumor necrosis factor multivalent NANOBODY compound ozoralizumab in patients with rheumatoid arthritis","volume":"74","author":"Takeuchi","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.02.004_bib0015","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/mr\/roac119","article-title":"Efficacy and safety of the anti-TNF multivalent NANOBODY\u00ae compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 52-week result of a Phase II\/III study (OHZORA trial)","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ard.2026.02.004_bib0016","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/mr\/roac126","article-title":"Efficacy and safety of anti-TNF multivalent NANOBODY\u00ae compound \u2018ozoralizumab\u2019 without methotrexate co-administration in patients with active rheumatoid arthritis: a 52-week result of phase III, randomised, open-label trial (NATSUZORA trial)","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ard.2026.02.004_bib0017","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13075-023-03036-4","article-title":"Efficacy and pharmacokinetics of ozoralizumab, an anti-TNF\u03b1 NANOBODY\u00ae compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials","volume":"25","author":"Takeuchi","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2026.02.004_bib0018","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/mr\/road097","article-title":"Effect of the extended dosing interval of anti-TNF-\u03b1 NANOBODY\u00ae compound ozoralizumab in patients with low disease activity rheumatoid arthritis","volume":"34","author":"Takeuchi","year":"2024","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ard.2026.02.004_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004480","article-title":"Long-term safety and efficacy of anti-TNF multivalent VHH antibodies ozoralizumab in patients with rheumatoid arthritis","volume":"10","author":"Tanaka","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2026.02.004_bib0020","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2026.02.004_bib0021","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2026.02.004_bib0022","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.004_bib0023","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2026.02.004_bib0024","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/art.30129","article-title":"American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"63","author":"Felson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2026.02.004_bib0025","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"Felson","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.004_bib0026","first-page":"167","article-title":"The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation","volume":"30","author":"Bruce","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2026.02.004_bib0027","first-page":"261","article-title":"How to read radiographs according to the Sharp\/van der Heijde method","volume":"27","author":"van der Heijde","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2026.02.004_bib0028","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/annrheumdis-2014-206696","volume":"75","author":"Fautrel","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.004_bib0029","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1001\/jama.2021.4542","article-title":"Effect of half-dose vs stable-dose conventional synthetic disease-modifying antirheumatic drugs on disease flares in patients with rheumatoid arthritis in remission: the ARCTIC REWIND randomized clinical trial","volume":"325","author":"Lillegraven","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ard.2026.02.004_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000147","article-title":"Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry","volume":"1","author":"Manders","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2026.02.004_bib0031","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000363","article-title":"Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study","volume":"3","author":"Takahashi","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2026.02.004_bib0032","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jbspin.2008.11.009","article-title":"Effect of discontinuing TNF\u03b1 antagonist therapy in patients with remission of rheumatoid arthritis","volume":"76","author":"Brocq","year":"2009","journal-title":"Joint Bone Spine"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726000798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726000798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:21:16Z","timestamp":1780820476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726000798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0003496726000798"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.02.004","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity: a randomised, controlled trial (SORAIRO trial)","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}